FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Metadata referenced "Fennec Pharmaceuticals," but the filing is for Adherex Technologies Inc.)
Reporting Period: Quarterly period ended June 30, 2009 (Form 10-Q).
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics (eniluracil, ADH-1, and sodium thiosulfate/STS).
Going Concern Status: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern. Cash reserves are projected to fund operations only into December 2009. If additional financing is not secured in the very near term, the company may cease operations sooner.

Key Financial Metrics

Note: All figures are in thousands of U.S. dollars. The company has no revenue and has incurred losses since inception in 1996.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly compared to the prior year periods.
  • Three Months: Expenses dropped from $3.5 million (Q2 2008) to $0.96 million (Q2 2009), a decrease of approximately 73%.
  • Six Months: Expenses dropped from $7.9 million (H1 2008) to $2.9 million (H1 2009), a decrease of approximately 63%.
• Drivers of Change: The reduction is primarily attributed to a 75% reduction in employee headcount effective April 2009 and the termination of the topical eniluracil study.
• Asset Impairment: The company recorded a $329,000 loss on impairment of assets held for sale and leasehold inducements for the six months ended June 30, 2009. No such impairment was recorded in the comparable 2008 period.
• Cash Position: Cash and cash equivalents declined from $5.3 million at December 31, 2008, to $1.5 million at June 30, 2009, reflecting the burn rate despite cost-cutting measures.

Outlook, Risks, and Management Commentary

• Strategic Pivot: Management announced a focus on the development of oral eniluracil combined with 5-FU, targeting a Phase II study within 6-9 months, contingent on funding. The topical eniluracil program was terminated.
• Liquidity Crisis: Management projects cash will last only until December 2009. The company is actively seeking strategic alternatives, including collaborations, equity sales, or debt issuance. Failure to secure funding may result in ceasing operations.
• Management Turnover: Significant leadership changes occurred in July 2009 (post-period end but disclosed as subsequent events). The CEO, CFO, and several directors resigned. New leadership was appointed, including Rosty Raykov as CEO and Robert Andrade as CFO.
• Key Risks:
  • Going Concern: Inability to raise capital is the primary existential risk.
  • Delisting: Common stock was delisted from the NYSE Alternext US (AMEX) in January 2009 and now trades on the OTC "pink sheets." There is a risk of delisting from the Toronto Stock Exchange (TSX) if listing requirements are not met.
  • Development Risk: Product candidates are in early stages; clinical trials may fail, and regulatory approval is uncertain.
  • Concentration of Ownership: Southpoint Capital Advisory LP beneficially owns approximately 42% of the company, giving them significant influence over corporate decisions.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured financing to extend operations beyond the projected December 2009 date.
• Management Stability: Assess the integration and track record of the new CEO (Rosty Raykov) and CFO (Robert Andrade) appointed in July 2009.
• Listing Status: Confirm the current listing status on the Toronto Stock Exchange (TSX) and compliance with minimum market capitalization requirements.
• Asset Sales: Monitor the progress of the sale of assets held for sale (laboratory equipment, furniture) to generate immediate liquidity.
• Strategic Partnerships: Investigate any new collaboration agreements or licensing deals that could provide upfront payments or milestone funding.